Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra survey

This article was originally published in The Tan Sheet

Executive Summary

Ephedrine alkaloid-containing supplement sales rose 76% in 1999 to 3.09 bil. servings, with manufacturers reporting only 25 "serious adverse events" during the year for a total of 8.1 AERs per billion servings, down from 8.6 AERs per billion servings in 1998, according to an AHPA-sponsored industry survey conducted by Arthur Andersen. The survey was mailed to 42 companies, with 14 responding. All respondents said they use a cautionary statement on labeling and identify their products as containing ephedra or ma huang. All of the products recommend a maximum daily intake of 100 mg or less of ephedrine alkaloids, and all but one of the products have a recommended maximum serving amount of 25 mg or less. All 14 companies said they have a collection system in place for serious AERs

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel